Predicting clinically significant drug interactions is an important part of benefit-risk assessment during the development of potential antipsychotic drugs. Ace Therapeutics offers comprehensive in vitro drug interaction assessment services. Our reliable data provides valuable insight that complements the pharmacokinetic information of your antipsychotic candidates. With our services, you can accelerate your antipsychotic development program by evaluating the risk of drug-drug interactions and optimizing drug development and dosing strategies.

Purpose of In Vitro Drug Interactions Assessment

Drug-drug interactions (DDI) refer to the pharmacokinetic and pharmacodynamic changes between drugs when multiple drugs are used concurrently. DDI assessment is an important component of antipsychotic drug development and regulatory evaluation. The absorption, distribution, metabolism, and excretion (ADME) process is influenced by the activity or level of metabolizing enzymes and transporters, which can be affected by the presence of multiple drugs. This can result in changes to the pharmacokinetics (PK) and pharmacodynamics of the drug in various organs, tissues, and body fluids where DDI occurs.

The objectives of our in vitro DDI studies in antipsychotic drug development include the following:

• Identification of the main routes of elimination of the drug.
• Assess the impact of relevant metabolic enzymes and transporters on the drug disposition.
• Assess the impact of pharmaceuticals on metabolic enzymes and transporters.
• Predicting the likelihood of clinical drug interactions and determining when and what in vivo drug interaction studies are needed.

In Vitro Drug Interactions Assessment Services of Antipsychotics

Ace Therapeutics provides in vitro drug interaction studies to assist clients in evaluating the pharmacokinetic profiles of antipsychotic candidates. This allows for a preliminary estimate of potential mechanisms and the severity of pharmacokinetic interactions, as well as the timing of DDI clinical studies.

Our company offers a range of specialized services, including:

• Assessment of metabolizing enzyme (mainly cytochrome P450 Enzyme) mediated drug interactions

We provide comprehensive metabolizing enzyme-mediated drug-drug interaction assessment services, including the study of drug-metabolizing enzyme phenotypes, the assessment of drug-metabolizing enzyme inhibition, and the assessment of drug-metabolizing enzyme induction. Our process relies on in vitro enzyme activity assays, such as in vitro enzyme inhibition assays and enzyme induction assays, to determine whether the drug to be tested interferes with the metabolic processes of other drugs.

• Assessment of transporter-mediated drug interactions

Ace Therapeutics examines the interaction of the drug under evaluation with specific drug transporters (e.g., P-glycoprotein, OATP, etc.). Our highly experienced experts evaluate the inhibitory or inducing effect of the drug of interest on the transporter by measuring the transporter-mediated drug transport activity using in vitro cell line or membrane slice techniques.

Advantages of Ace Therapeutics

• We provide tailored solutions to address the requirements for drug-drug interaction testing at various stages of antipsychotic drug discovery and development, including lead discovery, lead optimization, preclinical candidates, and NDA filing.
• A variety of methods and study types are employed to assist clients in maximizing DDI information throughout the drug discovery and development process. These include but are not limited to, cytochrome P450 enzyme reversible inhibition assays, cytochrome P450 enzyme metabolic response phenotyping assays, cytochrome P450 enzyme induction assays, and more.
• We strictly control the experimental process to ensure the accuracy and reliability of the data and provide detailed experimental reports and data analysis.

Ace Therapeutics is dedicated to facilitating the discovery and development of potential antipsychotics through our in vitro drug interaction testing platform. We can effectively predict the risk of drug interactions and inform clinical drug interaction study protocols. Please contact us for more details and we will be happy to assist you.